antibody

CYP1B1 Polyclonal Antibody

MBS126962

0.05 mL

230 USD

polyclonal

rabbit

nonconjugated

human, mouse, rat

western blot, immunohistochemistry

Antibody

CYP1B1 Polyclonal Antibody

CYP1B1

CP1B; GLC3A; P4501B1; CYP1B1

Cytochrome P450 1B1; Cytochrome P450 1B1; cytochrome P450 1B1; microsomal monooxygenase; xenobiotic monooxygenase; aryl hydrocarbon hydroxylase; flavoprotein-linked monooxygenase; cytochrome P450, subfamily I (dioxin-inducible), polypeptide 1 (glaucoma 3, primary infantile); cytochrome P450, family 1, subfamily B, polypeptide 1; CYPIB1

CYP1B1

CYP1B1; CYP1B1; CP1B; GLC3A; CYPIB1; P4501B1

CP1B1_HUMAN

Polyclonal

IgG

Rabbit

Human, Mouse, Rat

543

Affinity Purification

1mg/ml

Store at -20 degree C (regular) or -80 degree C (long term). Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Western Blot (WB), Immunohistochemistry (IHC)

WB: 1:500 - 1:2000. IHC: 1:50 - 1:200

Species: Human. Immunogen: Recombinant Protein

Immunogen: Recombinant protein of human CYP1B1. Calculated Molecular Weight: 61kDa

Polyclonal

Cytochrome P450 1B1 (CYP1B1) is a key enzyme involved in the production of potentially carcinogenic estrogen metabolites and the activation of environmental carcinogens and is the predominant member of the CYP1 family expressed in normal breast tissue and breast cancer. Estrogen has been proposed to trigger breast cancer development via an initiating mechanism involving its metabolite, catechol estrogen (CE). CYP1B1 catalyzes the conversion of 17-beta-estradiol to the catechol estrogen metabolites 2-OH-E2 and 4-OH-E2 which have both been postulated to be involved in mammary carcinogenesis. Genetic polymorphisms in CYP1B1 may play an important role in human prostate carcinogenesis as well. Polymorphism of the CYP1B1 gene at codon 432 (Val-->Leu) is associated with a change in catalytic function.

48429256

Q16678.2

Q16678

543

AhR Pathway (755436); Arachidonic Acid Metabolism Pathway (685553); Benzo(a)pyrene Metabolism Pathway (198911); Biological Oxidations Pathway (105698); Chemical Carcinogenesis Pathway (673221); Chemical Carcinogenesis Pathway (673237); Cytochrome P450 - Arranged By Substrate Type Pathway (105700); Defective CYP11A1 Causes Adrenal Insufficiency, Congenital, With 46,XY Sex Reversal (AICSR) Pathway (1127640); Defective CYP11B1 Causes Adrenal Hyperplasia 4 (AH4) Pathway (1127641); Defective CYP11B2 Causes Corticosterone Methyloxidase 1 Deficiency (CMO-1 Deficiency) Pathway (1127642)

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. The enzyme encoded by this gene localizes to the endoplasmic reticulum and metabolizes procarcinogens such as polycyclic aromatic hydrocarbons and 17beta-estradiol. Mutations in this gene have been associated with primary congenital glaucoma; therefore it is thought that the enzyme also metabolizes a signaling molecule involved in eye development, possibly a steroid. [provided by RefSeq, Jul 2008]

CYP1B1: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Defects in CYP1B1 are the cause of primary congenital glaucoma type 3A (GLC3A). GLC3A is an autosomal recessive form of primary congenital glaucoma (PCG). PCG is characterized by marked increase of intraocular pressure at birth or early childhood, large ocular globes (buphthalmos) and corneal edema. It results from developmental defects of the trabecular meshwork and anterior chamber angle of the eye that prevent adequate drainage of aqueous humor. Defects in CYP1B1 are a cause of primary open angle glaucoma (POAG). POAG is a complex and genetically heterogeneous ocular disorder characterized by a specific pattern of optic nerve and visual field defects. The angle of the anterior chamber of the eye is open, and usually the intraocular pressure is increased. The disease is asymptomatic until the late stages, by which time significant and irreversible optic nerve damage has already taken place. In some cases, POAG shows digenic inheritance involving mutations in CYP1B1 and MYOC genes. Defects in CYP1B1 are a cause of Peters anomaly (PAN). Peters anomaly is a congenital defect of the anterior chamber of the eye. Belongs to the cytochrome P450 family. Protein type: Oxidoreductase; Xenobiotic Metabolism - metabolism by cytochrome P450; EC 1.14.14.1; Amino Acid Metabolism - tryptophan. Chromosomal Location of Human Ortholog: 2p22.2. Cellular Component: endoplasmic reticulum membrane; mitochondrion. Molecular Function: iron ion binding; heme binding; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen; oxygen binding; monooxygenase activity. Biological Process: steroid metabolic process; estrogen metabolic process; collagen fibril organization; retinal metabolic process; positive regulation of apoptosis; response to toxin; positive regulation of JAK-STAT cascade; negative regulation of cell proliferation; visual perception; retinol metabolic process; arachidonic acid metabolic process; angiogenesis; nitric oxide biosynthetic process; cell adhesion; negative regulation of cell adhesion mediated by integrin; negative regulation of cell migration; epoxygenase P450 pathway; positive regulation of angiogenesis; inhibition of NF-kappaB transcription factor; xenobiotic metabolic process; toxin metabolic process; endothelial cell migration; blood vessel morphogenesis; aromatic compound metabolic process; membrane lipid catabolic process; induction of apoptosis by oxidative stress; sterol metabolic process. Disease: Peters Anomaly; Glaucoma 3, Primary Congenital, A; Glaucoma 3, Primary Infantile, B

0.05 mL

230 USD

0.1 mL

305

0.2 mL

460